Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Rating Reaffirmed by Jefferies Group LLC

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)‘s stock had its “hold” rating reiterated by investment analysts at Jefferies Group LLC in a research note issued to investors on Friday. They presently have a $2.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s price objective indicates a potential upside of 8.70% from the company’s previous close.

Several other analysts also recently commented on the stock. Piper Jaffray Companies restated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $1.80.

Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 1.84 on Friday. Arrowhead Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $8.22. The company’s market cap is $137.58 million. The stock has a 50 day moving average of $1.62 and a 200 day moving average of $1.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The firm had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.04%. Equities analysts expect that Arrowhead Pharmaceuticals will post ($0.52) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “[[title]]” was published by [[site]] and is the sole property of of [[site]]. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at [[permalink]].

A number of hedge funds have recently made changes to their positions in the stock. LMR Partners LLP bought a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth about $467,000. Wells Fargo & Company MN increased its stake in shares of Arrowhead Pharmaceuticals by 144.8% in the first quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after buying an additional 88,933 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock worth $186,000 after buying an additional 74,776 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock worth $123,000 after buying an additional 53,500 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Arrowhead Pharmaceuticals by 3.4% in the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after buying an additional 21,654 shares in the last quarter. Institutional investors own 30.14% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.